Jeong-Sun Han

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Key Words: Aderenergic agonist brimonidine diabetic retinopathy neuroprotection retinal ganglion cell Neurodegeneration is a critical component of diabetic retinopathy (DR), given the complex nature of the retina as a neurovascular unit rather than solely a vascular system (1, 2). Increasing evidence suggests that early retinal neurodegeneration occurs before vascular abnormalities become visible in the retina (3, 4).